Sansheng Guojian Releases Earnings Brief, Projected Revenue of 4.199 Billion Yuan in 2025, Up 251.81% Year-over-Year. Net Profit of 2.939 Billion Yuan, Up 317.09% Year-over-Year. During the reporting period, the company reached a significant partnership with Pfizer Inc., receiving an upfront licensing fee for Project 707 and recognizing approximately 2.89 billion yuan in revenue.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sansheng Guojian: Net profit of 2.939 billion yuan in 2025, a year-on-year increase of 317.09%
Sansheng Guojian Releases Earnings Brief, Projected Revenue of 4.199 Billion Yuan in 2025, Up 251.81% Year-over-Year. Net Profit of 2.939 Billion Yuan, Up 317.09% Year-over-Year. During the reporting period, the company reached a significant partnership with Pfizer Inc., receiving an upfront licensing fee for Project 707 and recognizing approximately 2.89 billion yuan in revenue.